Nuveen Asset Management LLC cut its position in Perrigo Company (NYSE:PRGO) by 14.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,838 shares of the company’s stock after selling 1,132 shares during the period. Nuveen Asset Management LLC’s holdings in Perrigo were worth $454,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Achmea Investment Management B.V. bought a new position in Perrigo during the first quarter worth $742,000. Bank of Nova Scotia increased its position in Perrigo by 2.5% in the first quarter. Bank of Nova Scotia now owns 3,219 shares of the company’s stock valued at $214,000 after buying an additional 80 shares during the last quarter. Janus Capital Management LLC increased its position in Perrigo by 2.6% in the first quarter. Janus Capital Management LLC now owns 98,304 shares of the company’s stock valued at $6,527,000 after buying an additional 2,501 shares during the last quarter. HighTower Advisors LLC increased its position in Perrigo by 271.7% in the first quarter. HighTower Advisors LLC now owns 35,775 shares of the company’s stock valued at $2,384,000 after buying an additional 26,151 shares during the last quarter. Finally, Blue Sky Asset Management LLC acquired a new position in Perrigo during the first quarter valued at approximately $1,047,000. 76.38% of the stock is currently owned by institutional investors and hedge funds.
Perrigo Company (NYSE PRGO) traded up 1.64% during midday trading on Monday, reaching $75.69. 64,836 shares of the company’s stock were exchanged. Perrigo Company has a 52 week low of $65.47 and a 52 week high of $99.14. The firm has a 50-day moving average price of $73.99 and a 200 day moving average price of $73.46. The company’s market cap is $10.85 billion.
Perrigo (NYSE:PRGO) last released its quarterly earnings data on Tuesday, May 30th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.19 billion. Perrigo had a negative net margin of 43.81% and a positive return on equity of 11.79%. Perrigo’s revenue for the quarter was down 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.32 EPS. Analysts anticipate that Perrigo Company will post $4.28 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://stocknewstimes.com/2017/07/31/nuveen-asset-management-llc-cuts-stake-in-perrigo-company-prgo.html.
Several equities analysts have commented on the stock. Cantor Fitzgerald set a $85.00 target price on shares of Perrigo and gave the stock a “buy” rating in a research report on Monday, July 24th. Royal Bank Of Canada set a $60.00 target price on shares of Perrigo and gave the stock a “sell” rating in a research report on Sunday, July 16th. Deutsche Bank AG reissued a “buy” rating and set a $88.00 target price (up from $86.00) on shares of Perrigo in a research report on Monday, July 17th. BidaskClub raised shares of Perrigo from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Finally, ValuEngine downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $84.97.
About Perrigo
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.
